Home>>Signaling Pathways>> GPCR/G protein>> Adrenergic Receptor>>Levalbuterol tartrate

Levalbuterol tartrate Sale

(Synonyms: 左旋沙丁胺醇酒石酸盐,Levosalbutamol tartrate) 目录号 : GC36441

Levalbuterol HCl(Levosalbutamol tartrate) is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.

Levalbuterol tartrate Chemical Structure

Cas No.:661464-94-4

规格 价格 库存 购买数量
10mg
¥736.00
现货
50mg
¥3,097.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Levalbuterol HCl(Levosalbutamol tartrate) is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.

Racemic albuterol (7.5 mg, bid) results in a greater improvement in their forced expiratory volume in 1 second (FEV1) as well as in their asthma scores after 1 hour of continuous treatment compared to the Levalbuterol (3.75 mg, bid) administration in children with asthma. The greater improvement in asthma scores is maintained after the second hour of continuous therapy in the racemic albuterol group but not for forced expiratory volume in 1 second (FEV1) measurements. [1] Levalbuterol (1.25 mg) requires significantly fewer median total nebulizations and scheduled nebulizations compared with those in the racemic albuterol (2.5 mg) group in patients with asthma or chronic obstructive pulmonary disease (COPD). Disease symptom assessment and subject general well-being score scores improves significantly from baseline in both levalbuterol (1.25 mg) and racemic albuterol (2.5 mg) treatment groups, and beta-mediated adverse effects mean scores are significantly greater with levalbuterol versus racemic albuterol. [2]

[1] Wilkinson M, et al. J Asthma, 2011, 48(2), 188-193. [2] Donohue JF, et al. Clin Ther, 2008, 30, 989-1002. [3] Cydulka RK, et al. J Asthma, 2010, 47(10), 1094-1100.

Chemical Properties

Cas No. 661464-94-4 SDF
别名 左旋沙丁胺醇酒石酸盐,Levosalbutamol tartrate
Canonical SMILES OC1=C(CO)C=C([C@@H](O)CNC(C)(C)C)C=C1.OC2=C(CO)C=C([C@@H](O)CNC(C)(C)C)C=C2.OC([C@H](O)[C@@H](O)C(O)=O)=O
分子式 C30H48N2O12 分子量 628.71
溶解度 Soluble in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.5906 mL 7.9528 mL 15.9056 mL
5 mM 0.3181 mL 1.5906 mL 3.1811 mL
10 mM 0.1591 mL 0.7953 mL 1.5906 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Trends in Medicaid spending on inhalers in the United States, 2012-2018

J Manag Care Spec Pharm 2021 Dec;27(12):1744-1749.PMID:34818085DOI:10.18553/jmcp.2021.27.12.1744.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and asthma are common respiratory diseases that impose a significant economic burden on Medicaid. Inhalers are the mainstay treatment for relieving symptoms and improving outcomes for COPD and asthma patients. OBJECTIVE: To describe the total spending and trends of Medicaid expenditures on inhalers between 2012 and 2018 in the United States. METHODS: We analyzed the deidentified data from the Medicaid Drug Spending Dashboard and utilization datasets from 2012 to 2018. We identified 9 classes of inhalers and described the Medicaid total spending on and relative annual changes for those inhalers. We also described the spending on available generic inhalers and compared the Medicaid spending by manufacturers during this time frame. RESULTS: Medicaid spent $26.2 billion on inhalers from 2012 to 2018. This spending increased by $2.5 billion (120%) over this time frame. During this specified period, the highest Medicaid spending was on the group of inhaled corticosteroid (ICS)-containing inhalers ($14.9 billion). Within this group, the inhaler class of ICS/long-acting beta-2 adrenoceptor agonists contributed to the highest Medicaid spending (53%), with a growth of 607% between 2012 and 2018. Of the $26.2 billion that Medicaid spent on inhalers, $35.5 million (less than 0.01%) was spent on 2 generic inhalers: fluticasone propionate with salmeterol and Levalbuterol tartrate hydrofluoroalkane. CONCLUSIONS: Between 2012 and 2018, on average, $3.5 billion per year was spent by Medicaid on inhalers. Decreasing the price of inhalers by introducing more generic inhalers in the market can potentially reduce the cost burden on Medicaid. DISCLOSURES: This study was funded by the American Foundation for Pharmaceutical Education (AFPE). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflicts of interest.

Practical methods for improving flow properties of active pharmaceutical ingredients

Drug Dev Ind Pharm 2009 Dec;35(12):1460-9.PMID:19929205DOI:10.3109/03639040903025830.

Objective: The essential aim of this article is to develop effective methods for improving the flow properties of active pharmaceutical ingredients (APIs) without requiring particle size or shape modification. Methods: The 'formulation' approach used here focuses on enhancing flow properties of three chemically different drug powders (micronized acetaminophen, Levalbuterol tartrate, and didesmethylsibutramine tartrate) by using small amounts of lubricants, glidants, and other additives, both individually and in combination. Additives are intimately mixed using a laboratory-scale V-blender with an intensifier bar. Flow index, dilation, and electrical impedance were measured for a total of 24 blends. Results: The flow behavior of all three APIs improved with the addition of these additives. Relative effectiveness of different additive combinations displayed remarkable consistency for all three APIs. Simultaneous presence of SiO2, MgSt, and talc led to substantial decreases in cohesiveness, causing major improvements in flowability of powder. All three properties showed a very tight correlation. Conclusions: Drug powders with improved flow were found to exhibit low dilation and low impedance values. A common linear correlation between flow index and impedance and also between dilation and impedance was observed for all three APIs, indicating that electric properties play a substantial role in the cohesivity of all three APIs, and suggesting the presence of a common mechanism for the emergence (and mitigation) of cohesive phenomena.